SNYR Stock Forecast & Price Target

Synergy CHC Corp reported a net revenue of $8.0 million, reflecting a 12% increase from the previous year, indicating a positive growth trajectory despite being approximately 27% below estimates. The company experienced a slight increase in gross margin to 67.2%, primarily due to a shift towards higher-margin supplement revenues, suggesting improved profitability potential. Furthermore, the anticipated progress in sales, product development, and market expansion, particularly with the FOCUSfactor brand, is likely to enhance visibility into future revenues and cash flows, ultimately benefiting shareholders in the long term.

Synergy CHC Corp reported an Adjusted EBITDA of $1.3 million, unchanged from the previous year but significantly below the anticipated $2.4 million, reflecting challenges stemming from tightened cash flow prior to a recent equity raise. Additionally, there has been a downward revision in revenue estimates, with projections for 2025 now at $35.4 million, reduced from $43.2 million, further signaling weakening performance. Lastly, the company's stock has exhibited considerable volatility and weakness over the past year, contributing to an overall negative outlook amid deteriorating economic conditions that typically depress consumer spending.